Greenstone Biosciences
Your Trusted NAMs Partner
Accelerating the New Approach Methodologies (NAMs)-Driven Revolution in Drug Discovery — innovative, human-relevant technologies that reduce reliance on animal testing and enable faster, safer, and more cost-effective drug development.
Greenstone Biosciences has the world’s largest human iPSC biobank, generated from more than 2500 individuals. Our biobank also represents the world’s largest collection of iPSCs derived from rare orphan disease patients.
Greenstone Biosciences
Your Trusted NAMs Partner
Advanced Human-Relevant Organoid systems
- The world's largest human iPSC biobank, spanning 2,500+ individuals
- Unmatched rare disease coverage with the world's largest orphan disease cell line collection
- Free open-access resource for academic investigators — no cost, no barriers
- Mechanistic insight into human disease at the cellular level
- High-throughput safety and efficacy screening built for speed and scale
- Personalized medicine solutions grounded in your patient's own biology
Revolutionizing Drug Discovery with iPSC and AI
Greenstone Biosciences is revolutionizing drug discovery. We leverage cutting-edge human iPSC-based New Approach Methodologies (NAMs) using 3D organoids and advanced human micro-physiological systems, and Artificial Intelligence (AI) technologies.
Advance your research: Sign up for expert insights, new product alerts, and exclusive webinar invitations.
Wu et al., Science (2026)
About Us
Greenstone Biosciences is a biotech innovator based in Stanford Research Park. We operate at the intersection of regulatory change and technological advancement, driven by the belief that New Alternative Methods, or New Approach Methodologies (NAMs)—and other human-relevant models—are reshaping the future of medicine. Building on this foundation, we combine:
Our Services
Greenstone Biosciences offers advanced iPSC-based solutions and AI-powered platforms to accelerate drug discovery. From patient-derived models to high-throughput screening and organoid assays, our services deliver human-relevant insights that drive safer, more effective therapies.
PBMC Collection and iPSC Reprogramming
Custom Differentiated iPSCs
Genetically Engineered iPSCs
High-throughput Drug Discovery
Cell Village
Clinical Trial in a Dish
CARTOX (hERG Toxicity Assay)
Hepatotoxicity Screen
Brain Organoids for Screening BBB Penetration and Neurotoxicity
Functional Assays of Gut Barrier Integrity and Disease Modelling
Pancreatic Islet Organoid – Glucose Sensitivity
Organoids for Assessing Immune Responses
Why choose Us
Why Greenstone is Different
Testimonials
What Our Clients Say
Discover how our solutions are helping teams advance drug discovery and deliver meaningful results.
Christopher Chen
MD, PhD ( William F. Warren Distinguished Professor of Biomedical Engineering, Boston University)
"My experience working with the GSB-L550 HCM patient-derived hiPSC line from Greenstone Biosciences Inc. has been excellent. The cells were straightforward to thaw and consistently differentiated into cardiomyocytes with high efficiency. Incorporating this line into our study allowed us to expand our findings to include additional HCM-related mutations without the need to generate new lines in-house. Overall, these cells are a reliable and valuable resource that I would strongly recommend to other research laboratories."
J. David Becherer
CSO, CO-Founder - Neolaia
“Greenstone Bioscience has been an exceptional scientific partner. Their advanced human iPSC-derived models, collaborative approach, and consistently rigorous, reproducible data have made them a valuable contributor to our drug development efforts. They are responsive, dependable, and thoughtful, and we view them as a true, indispensable partner in advancing complex scientific programs.”
Gordana Vunjak-Novakovic
PhD (Mikati Foundation Professor Of Biomedical Engineering And Medical Sciences; Professor Of Dental Medicine, Columbia University)
“We had a very positive experience working with Greenstone Biosciences’ hiPSC lines. The GSB-L2177 cells demonstrated strong reproducibility, robust cardiac differentiation performance, and clear disease-relevant phenotypes consistent with the patient’s clinical presentation. The quality and consistency of the cells were important for enabling our work. Overall, we appreciate both the quality of the cell lines and the responsiveness of the Greenstone team throughout the process.”
Bettina Lickiss
PhD InnoVitro
"We used Greenstone Biosciences' cryopreserved hiPSC-CMs for a recent customer project and were very pleased with the product performance. The cells were easy to handle and showed efficient adherence to 96-well FLEXcyte plates. The CMs started contracting two to three days after plating and provided excellent contraction data."
Our Products
Innovative Cellular Models for Research & Therapy
Unlock the power of human biology with our advanced platforms. Greenstone Biosciences offers hiPSC-derived cells and organoids that accelerate translational research, reduce clinical risks, and drive the development of safer, more effective therapies.
hiPSC-Derived Cells
- Unlimited self-renewal capacity
- Patient-specific disease modeling
- High relevance for drug discovery
- Scalable & reproducible supply
- Foundation for personalized medicine
Organoids
- Organoids generated from iPSCs
- 3D organ-like tissue models
- Replicate real organ structure & function
- Enable advanced disease modeling
- High predictive accuracy for drug testing
- Customizable for precision medicine research
Join Us in Shaping the Future of Drug Discovery
Partner with us to accelerate breakthroughs using iPSC and AI-powered platforms.
Upcoming Webinars
Publications
Greenstone scientists and collaborators regularly publish in peer-reviewed publications to inform the scientific community of discoveries from Greenstone labs and our collaborators.
Induced pluripotent stem cells from discovery to translation
Two decades after the introduction of induced pluripotent stem cell (iPSC) technology, the...